Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
NASDAQ:NCNA

NuCana Earnings Date & Estimates

NuCana logo
$1.01 +0.03 (+2.91%)
Closing price 10/20/2026 03:59 PM Eastern
Extended Trading
$1.04 +0.04 (+3.82%)
As of 05:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NuCana is estimated to report earnings on Thursday, November 12, 2026.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from NuCana

NuCana is expected to post earnings of -$2.6522 per share. In the same quarter a year earlier NuCana reported -$0.10 per share. NuCana last reported on August 13, 2026, posting -$0.99 per share and beating the -$2.6514 consensus estimate. NuCana has beaten the consensus EPS estimate in 4 of its last 4 quarters.

Consensus Estimates

Consensus EPS
-$2.6522
Prior-Year EPS
-$0.10

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.99 (Beat by +$1.6614)
EPS Beat Rate
4 of last 4 quarters

Prepare for the Earnings Call

NuCana Earnings FAQ

NuCana (NASDAQ:NCNA) is estimated to report earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect NuCana to post earnings of -$2.6522 per share for the quarter.

NuCana Earnings Headlines

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
September 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/30/3371836/0/en/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe.html
NuCana Files Q2 2026 Results and Updates U.S. Registration Statements
August 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NCNA/pressreleases/3859915/nucana-files-q2-2026-results-and-updates-us-registration-statements/
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
October 21 at 1:00 AM  |  Banyan Hill Publishing (Ad)
NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344884/0/en/nucana-reports-second-quarter-2026-financial-results-and-provides-business-update.html
NuCana plc Sponsored ADR
June 16, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/NCNA
NuCana Appoints Ian Webster as Chief Financial Officer
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304314/0/en/nucana-appoints-ian-webster-as-chief-financial-officer.html
See More NuCana Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email.

About NuCana

NuCana (NASDAQ:NCNA) plc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company applies its ProTide technology platform to existing nucleoside analogues, with the goal of improving their delivery into tumor cells, increasing anticancer activity and overcoming mechanisms of drug resistance.

NuCana’s pipeline has included Acelarin (NUC-1031), a ProTide-based version of gemcitabine investigated in several solid tumors, including pancreatic, biliary tract and ovarian cancers. The company has also developed NUC-3373, a ProTide analogue of 5-fluorouracil, and NUC-7738, an investigational cancer therapy derived from a nucleoside analogue. These candidates have been evaluated in clinical studies, but NuCana has not reported a marketed commercial product.

NuCana was founded in 2008 and is headquartered in Edinburgh, Scotland. Its drug-development activities have involved clinical research in the United Kingdom, the United States and other international markets. The company has been led by Hugh Griffith, its chief executive officer and a co-founder, alongside a management and scientific team focused on oncology drug development.

View NuCana Profile
Earnings Tools